When Does Adding One More System Become an Operational Risk?

A site running 100 studies could theoretically touch 500 different systems.

Let’s do some intentionally ridiculous math.

In the 2026 State of Clinical Trial Technology Report, sites reported that they typically log into multiple study-specific systems for every trial they run.

The Systems a Single Site Manages

• EDC
• ePRO
• IVRS/IWRS
• sponsor portals
• imaging systems
• training systems
• lab systems
• and more

About half of site respondents reported using 5 or more study-specific systems per study.

How Many Studies Are Sites Actually Running?

Separately, we asked sites how many active studies they manage:

• 23% reported running more than 50 studies
• 15% reported running more than 100

So let’s combine those numbers.

If a site runs:

• 100 active studies
• with 5 study-specific systems per study

That site could theoretically interact with:

500 different study systems

To be clear, this is intentionally provocative math.

We know there’s repetition of platforms across studies and sponsors. Not every study introduces five completely unique technologies.

But that’s not really the point.

The point is that clinical research has evolved into an environment where every new study can potentially introduce:

• new workflows
• new credentials
• new training requirements
• new support processes
• new integrations
• new operational friction

And when you step back and look at the clinical trial technology landscape, it becomes easier to understand how we got here.

How the Industry Got Here

There are hundreds of vendors competing to solve highly specific workflow problems across virtually every operational function imaginable.

Innovation is good.

But somewhere along the way, the industry started optimizing individual workflow categories instead of operational simplicity.

The result is that sites increasingly operate inside layered technology ecosystems assembled one study at a time.

And unlike most enterprise software environments, sites rarely control the stack.

Sponsors and CROs choose systems.
Vendors change across studies.
Processes vary sponsor to sponsor.

Sites adapt.

Over and over again.

The industry talks a lot about interoperability, consolidation, and workflow orchestration.

But the reason those conversations matter is simple: clinical trial operations may be approaching the practical limits of human system management.

At some point, adding another system stops being a technology decision and becomes an operational risk.